BAY 3713372
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MTAP-deleted Solid Tumors
Conditions
MTAP-deleted Solid Tumors
Trial Timeline
Mar 21, 2025 → Jun 17, 2029
NCT ID
NCT06914128About BAY 3713372
BAY 3713372 is a phase 1/2 stage product being developed by Bayer for MTAP-deleted Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06914128. Target conditions include MTAP-deleted Solid Tumors.
Hype Score Breakdown
Clinical
9
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06914128 | Phase 1/2 | Recruiting |
Competing Products
3 competing products in MTAP-deleted Solid Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AMG 193 | Amgen | Phase 2 | 42 |
| BG-89894 | BeOne Medicines | Phase 1 | 33 |
| S095035 + TNG462 | Tango Therapeutics | Phase 1/2 | 33 |